Can Tests Reveal a CLL Patient’s Potential for Developing Treatment Resistance? | Transcript | Chronic Lymphocytic Leukemia | Patient Power


Can Tests Reveal a CLL Patient’s Potential for Developing Treatment Resistance?

And, two, is you really—you know, in essence when you look at the data that suggests that 92 percent of patients who get ibrutinib (Imbruvica) as a first-line therapy will remain in remission at five years you're talking about treating--or testing a lot of people for very, very few people that will likely benefit.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on September 9, 2019